CONTEXT: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal skeletal microarchitecture and variable tissue-level bone formation rate (BFR). OBJECTIVES: Compare 6 months (M) of teriparatide versus placebo on areal bone mineral density (aBMD) by dual-energy x-ray absorptiometry (DXA), bone turnover markers (BTMs) and BFR at 3M by quadruple-labeled transiliac biopsy. Characterize 12M and 24M effects of teriparatide on aBMD and whether BTMs and BFR predict response. DESIGN: 6M phase 2 randomized controlled trial (RCT) followed by open extension. SETTING: Tertiary referral centers. PATIENTS: Premenopausal women with IOP. INTERVENTIONS: A total of 41 women were randomized to either teriparatide 20 mcg (n = 28) or placebo (n = 13). After 6M, those on placebo switched to teriparatide for 24M; those on teriparatide continued for 18M. MAIN OUTCOME MEASURES: 6M RCT: Between-group differences in lumbar spine (LS) aBMD (percent change from baseline), 3M BFR, and hypercalcemia. Open-label extension: Within-group change in LS aBMD over 12M and 24M. Secondary outcomes included aBMD change at other sites and relationship between BTMs, BFR, and changes in aBMD. FINDINGS: Over 6M, LS aBMD increased by 5.5% (95% CI: 3.83, 7.19) in teriparatide and 1.5% (95% CI: -0.73, 3.83) in placebo (P = 0.007). There were increases in 3M BTMs, and BFR (cancellous and endocortical BFR: between-groups P = 0.004). Over 24M, teriparatide increased LS aBMD by 13.2% (95% CI: 10.3, 16.2), total hip by 5.2% (95% CI: 3.7, 6.7) and femoral neck by 5.0% (95% CI: 3.2, 6.7; all P ≤ 0.001). Serum N-terminal propeptides of procollagen type 1 (P1NP) and 3M endocortical BFR were moderately associated with LS aBMD response. Teriparatide was well-tolerated. CONCLUSIONS: Teriparatide increased BFR and formation markers and was associated with marked aBMD improvements in most premenopausal women (82%) with IOP. Published by Oxford University Press on behalf of the Endocrine Society 2020.
CONTEXT: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal skeletal microarchitecture and variable tissue-level bone formation rate (BFR). OBJECTIVES: Compare 6 months (M) of teriparatide versus placebo on areal bone mineral density (aBMD) by dual-energy x-ray absorptiometry (DXA), bone turnover markers (BTMs) and BFR at 3M by quadruple-labeled transiliac biopsy. Characterize 12M and 24M effects of teriparatide on aBMD and whether BTMs and BFR predict response. DESIGN: 6M phase 2 randomized controlled trial (RCT) followed by open extension. SETTING: Tertiary referral centers. PATIENTS: Premenopausal women with IOP. INTERVENTIONS: A total of 41 women were randomized to either teriparatide 20 mcg (n = 28) or placebo (n = 13). After 6M, those on placebo switched to teriparatide for 24M; those on teriparatide continued for 18M. MAIN OUTCOME MEASURES: 6M RCT: Between-group differences in lumbar spine (LS) aBMD (percent change from baseline), 3M BFR, and hypercalcemia. Open-label extension: Within-group change in LS aBMD over 12M and 24M. Secondary outcomes included aBMD change at other sites and relationship between BTMs, BFR, and changes in aBMD. FINDINGS: Over 6M, LS aBMD increased by 5.5% (95% CI: 3.83, 7.19) in teriparatide and 1.5% (95% CI: -0.73, 3.83) in placebo (P = 0.007). There were increases in 3M BTMs, and BFR (cancellous and endocortical BFR: between-groups P = 0.004). Over 24M, teriparatide increased LS aBMD by 13.2% (95% CI: 10.3, 16.2), total hip by 5.2% (95% CI: 3.7, 6.7) and femoral neck by 5.0% (95% CI: 3.2, 6.7; all P ≤ 0.001). Serum N-terminal propeptides of procollagen type 1 (P1NP) and 3M endocortical BFR were moderately associated with LS aBMD response. Teriparatide was well-tolerated. CONCLUSIONS: Teriparatide increased BFR and formation markers and was associated with marked aBMD improvements in most premenopausal women (82%) with IOP. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Entities:
Keywords:
bone biopsy; bone turnover markers; premenopausal osteoporosis; teriparatide
Authors: Robert Lindsay; Felicia Cosman; Hua Zhou; Mathias P Bostrom; Victor W Shen; JoAnn D Cruz; Jeri W Nieves; David W Dempster Journal: J Bone Miner Res Date: 2005-11-21 Impact factor: 6.741
Authors: A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker Journal: J Bone Miner Res Date: 1987-12 Impact factor: 6.741
Authors: Christian Muschitz; Roland Kocijan; Judith Haschka; Dieter Pahr; Alexandra Kaider; Peter Pietschmann; Didier Hans; Gabriela Katharina Muschitz; Astrid Fahrleitner-Pammer; Heinrich Resch Journal: Bone Date: 2015-06-16 Impact factor: 4.398
Authors: B L Langdahl; F Marin; E Shane; H Dobnig; J R Zanchetta; M Maricic; K Krohn; K See; M R Warner Journal: Osteoporos Int Date: 2009-04-07 Impact factor: 4.507
Authors: David W Dempster; Juliet E Compston; Marc K Drezner; Francis H Glorieux; John A Kanis; Hartmut Malluche; Pierre J Meunier; Susan M Ott; Robert R Recker; A Michael Parfitt Journal: J Bone Miner Res Date: 2013-01 Impact factor: 6.741
Authors: Henry G Bone; Felicia Cosman; Paul D Miller; Gregory C Williams; Gary Hattersley; Ming-Yi Hu; Lorraine A Fitzpatrick; Bruce Mitlak; Socrates Papapoulos; René Rizzoli; Robin K Dore; John P Bilezikian; Kenneth G Saag Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: Adi Cohen; Joseph Hostyk; Evan H Baugh; Christie M Buchovecky; Vimla S Aggarwal; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Mafo Kamanda-Kosseh; Mariana Bucovsky; Julie Stubby; David B Goldstein; Elizabeth Shane Journal: Bone Date: 2021-11-04 Impact factor: 4.398
Authors: Sanchita Agarwal; Elizabeth Shane; Thomas Lang; Stephanie Shiau; Mafo Kamanda-Kosseh; Mariana Bucovsky; Joan M Lappe; Julie Stubby; Robert R Recker; Yizhong Hu; Zexi Wang; X Edward Guo; Adi Cohen Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134
Authors: Alice Costantini; Riikka E Mäkitie; Markus A Hartmann; Nadja Fratzl-Zelman; M Carola Zillikens; Uwe Kornak; Kent Søe; Outi Mäkitie Journal: J Bone Miner Res Date: 2022-09-11 Impact factor: 6.390
Authors: Jingzhu Zhang; Adi Cohen; Bo Shen; Liming Du; Alpaslan Tasdogan; Zhiyu Zhao; Elizabeth J Shane; Sean J Morrison Journal: Proc Natl Acad Sci U S A Date: 2021-06-22 Impact factor: 11.205